Literature DB >> 8836945

Anticholinergic therapy and dementia in patients with Parkinson's disease.

M Pondal1, T Del Ser, F Bermejo.   

Abstract

In a cross-sectional study performed in 1980 on 70 consecutive Parkinson's disease (PD) outpatients, we investigated the factors associated with dementia, especially anticholinergic drugs. All cases fulfilled three major clinical criteria of PD, and underwent extensive clinical and laboratory examinations, including brain CT and neuropsychological assessment. Cases with mental deterioration at the onset of the illness or confusional status were excluded. In 15 patients the diagnosis of dementia was made according to DSM-III criteria; 15 other non-demented patients scoring 4 on the Reisberg's Global Deterioration Scale were labelled as "mentally deteriorated", and the remaining 40 cases were considered cognitively normal. In a logistic multiple regression analysis only age, female sex and time of anticholinergic intake were significantly associated with dementia. We conclude that anticholinergic drugs must be avoided in PD patients with some cognitive decline.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8836945     DOI: 10.1007/bf00886877

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  16 in total

1.  An estimate of the prevalence of dementia in idiopathic Parkinson's disease.

Authors:  R Mayeux; Y Stern; R Rosenstein; K Marder; A Hauser; L Cote; S Fahn
Journal:  Arch Neurol       Date:  1988-03

2.  Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease.

Authors:  E K Perry; D Irving; J M Kerwin; I G McKeith; P Thompson; D Collerton; A F Fairbairn; P G Ince; C M Morris; A V Cheng
Journal:  Alzheimer Dis Assoc Disord       Date:  1993       Impact factor: 2.703

3.  Visuospatial impairment in Parkinson's disease.

Authors:  B E Levin; M M Llabre; S Reisman; W J Weiner; J Sanchez-Ramos; C Singer; M C Brown
Journal:  Neurology       Date:  1991-03       Impact factor: 9.910

4.  Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?

Authors:  B Pillon; B Dubois; G Cusimano; A M Bonnet; F Lhermitte; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-02       Impact factor: 10.154

5.  Age-induced cognitive disturbances in Parkinson's disease.

Authors:  B Dubois; B Pillon; N Sternic; F Lhermitte; Y Agid
Journal:  Neurology       Date:  1990-01       Impact factor: 9.910

6.  The Global Deterioration Scale for assessment of primary degenerative dementia.

Authors:  B Reisberg; S H Ferris; M J de Leon; T Crook
Journal:  Am J Psychiatry       Date:  1982-09       Impact factor: 18.112

7.  Confusion, dementia and anticholinergics in Parkinson's disease.

Authors:  Y de Smet; M Ruberg; M Serdaru; B Dubois; F Lhermitte; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-12       Impact factor: 10.154

8.  Cholinergic-dependent cognitive deficits in Parkinson's disease.

Authors:  B Dubois; F Danzé; B Pillon; G Cusimano; F Lhermitte; Y Agid
Journal:  Ann Neurol       Date:  1987-07       Impact factor: 10.422

9.  A clinicopathologic study of 100 cases of Parkinson's disease.

Authors:  A J Hughes; S E Daniel; S Blankson; A J Lees
Journal:  Arch Neurol       Date:  1993-02

10.  Chronic dementia in Parkinson's disease treated by anticholinergic agents. Neuropsychological and neuroradiological examination.

Authors:  K Nishiyama; T Mizuno; M Sakuta; H Kurisaki
Journal:  Adv Neurol       Date:  1993
View more
  4 in total

Review 1.  Pharmacological treatment of Parkinson's disease.

Authors:  A Münchau; K P Bhatia
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

Review 2.  Antimuscarinic Anticholinergic Medications in Parkinson Disease: To Prescribe or Deprescribe?

Authors:  Matthew J Barrett; Lana Sargent; Huma Nawaz; Daniel Weintraub; Elvin T Price; Allison W Willis
Journal:  Mov Disord Clin Pract       Date:  2021-10-08

Review 3.  Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

Authors:  Yahya E Choonara; Viness Pillay; Lisa C Du Toit; Girish Modi; Dinesh Naidoo; Valence M K Ndesendo; Sibongile R Sibambo
Journal:  Int J Mol Sci       Date:  2009-06-03       Impact factor: 6.208

Review 4.  Exploring the cognitive and motor functions of the basal ganglia: an integrative review of computational cognitive neuroscience models.

Authors:  Sebastien Helie; Srinivasa Chakravarthy; Ahmed A Moustafa
Journal:  Front Comput Neurosci       Date:  2013-12-06       Impact factor: 2.380

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.